Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
GERN's Cash to Debt is ranked higher than
89% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. GERN: No Debt )
GERN' s 10-Year Cash to Debt Range
Min: 0.87   Max: No Debt
Current: No Debt

Equity to Asset 0.97
GERN's Equity to Asset is ranked higher than
98% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. GERN: 0.97 )
GERN' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.97
Current: 0.97

0.37
0.97
F-Score: 4
Z-Score: 34.40
M-Score: 3.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -2899.43
GERN's Operating margin (%) is ranked higher than
52% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. GERN: -2899.43 )
GERN' s 10-Year Operating margin (%) Range
Min: -41916.67   Max: -149.32
Current: -2899.43

-41916.67
-149.32
Net-margin (%) -2842.67
GERN's Net-margin (%) is ranked higher than
52% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. GERN: -2842.67 )
GERN' s 10-Year Net-margin (%) Range
Min: -41504.17   Max: -131.51
Current: -2842.67

-41504.17
-131.51
ROE (%) -35.74
GERN's ROE (%) is ranked higher than
69% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. GERN: -35.74 )
GERN' s 10-Year ROE (%) Range
Min: -157.29   Max: -17.94
Current: -35.74

-157.29
-17.94
ROA (%) -33.75
GERN's ROA (%) is ranked higher than
67% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. GERN: -33.75 )
GERN' s 10-Year ROA (%) Range
Min: -85.77   Max: -14.86
Current: -33.75

-85.77
-14.86
ROC (Joel Greenblatt) (%) -19430.30
GERN's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. GERN: -19430.30 )
GERN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7309.19   Max: -89.68
Current: -19430.3

-7309.19
-89.68
Revenue Growth (%) -37.00
GERN's Revenue Growth (%) is ranked higher than
61% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. GERN: -37.00 )
GERN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 58.7
Current: -37

0
58.7
EBITDA Growth (%) -35.50
GERN's EBITDA Growth (%) is ranked higher than
58% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. GERN: -35.50 )
GERN' s 10-Year EBITDA Growth (%) Range
Min: -35.5   Max: 13.5
Current: -35.5

-35.5
13.5
EPS Growth (%) -35.90
GERN's EPS Growth (%) is ranked higher than
60% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. GERN: -35.90 )
GERN' s 10-Year EPS Growth (%) Range
Min: -35.9   Max: 32.5
Current: -35.9

-35.9
32.5
» GERN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

GERN Guru Trades in Q3 2013

Steven Cohen 700,000 sh (New)
Jean-Marie Eveillard 2,516,014 sh (-3.12%)
Chuck Royce 420,066 sh (-38.23%)
Jim Simons 86,580 sh (-92.11%)
» More
Q4 2013

GERN Guru Trades in Q4 2013

Paul Tudor Jones 18,396 sh (New)
Jean-Marie Eveillard 6,511 sh (unchged)
Jim Simons Sold Out
Chuck Royce Sold Out
Steven Cohen Sold Out
Jean-Marie Eveillard 2,085,827 sh (-17.1%)
» More
Q1 2014

GERN Guru Trades in Q1 2014

John Burbank 25,000 sh (New)
Jean-Marie Eveillard 3,054,252 sh (+46.43%)
Jean-Marie Eveillard 2,013 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

GERN Guru Trades in Q2 2014

Jean-Marie Eveillard 3,548,124 sh (+16.17%)
John Burbank 25,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GERN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Add 46.43%0.01%$1.6 - $5.4 $ 2.17-46%3054252
John Burbank 2014-03-31 New Buy$1.6 - $5.4 $ 2.17-46%25000
Jean-Marie Eveillard 2013-03-31 Add 36.91%$1.01 - $1.64 $ 2.1757%2410934
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.36
GERN's P/B is ranked higher than
86% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. GERN: 2.36 )
GERN' s 10-Year P/B Range
Min: 0.83   Max: 9.55
Current: 2.36

0.83
9.55
P/S 243.90
GERN's P/S is ranked lower than
53% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. GERN: 243.90 )
GERN' s 10-Year P/S Range
Min: 22.34   Max: 912.7
Current: 243.9

22.34
912.7
EV-to-EBIT -5.54
GERN's EV-to-EBIT is ranked higher than
57% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GERN: -5.54 )
GERN' s 10-Year EV-to-EBIT Range
Min: 7.3   Max: 35.3
Current: -5.54

7.3
35.3
Current Ratio 29.98
GERN's Current Ratio is ranked higher than
99% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. GERN: 29.98 )
GERN' s 10-Year Current Ratio Range
Min: 3.19   Max: 33.57
Current: 29.98

3.19
33.57
Quick Ratio 29.98
GERN's Quick Ratio is ranked higher than
99% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. GERN: 29.98 )
GERN' s 10-Year Quick Ratio Range
Min: 3.19   Max: 33.57
Current: 29.98

3.19
33.57

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.53
GERN's Price/Net Cash is ranked higher than
96% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 86.53 vs. GERN: 2.53 )
GERN' s 10-Year Price/Net Cash Range
Min: 1.45   Max: 223.42
Current: 2.53

1.45
223.42
Price/Net Current Asset Value 2.50
GERN's Price/Net Current Asset Value is ranked higher than
96% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 52.38 vs. GERN: 2.50 )
GERN' s 10-Year Price/Net Current Asset Value Range
Min: 1.45   Max: 141.11
Current: 2.5

1.45
141.11
Price/Tangible Book 2.36
GERN's Price/Tangible Book is ranked higher than
90% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. GERN: 2.36 )
GERN' s 10-Year Price/Tangible Book Range
Min: 1.25   Max: 18.35
Current: 2.36

1.25
18.35
Forward Rate of Return (Yacktman) -41.33
GERN's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. GERN: -41.33 )
GERN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9.1   Max: 33.2
Current: -41.33

9.1
33.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GON.Germany
Geron Corporation was incorporated in the State of Delaware on November 28, 1990. The Company is a biopharmaceutical company that develops therapies for cancer. Its clinical development product candidates include Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials for the treatment of metastatic breast cancer, advanced non-small cell lung cancer, thrombocythemia, and myeloma. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. The Company also develops pharmaceuticals that activate telomerase in tissues impacted by cell aging, injury or degenerative diseases; and cell-based therapies derived from human embryonic stem cells for treatment of various chronic diseases.
» More Articles for GERN

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: HTM, OVTI, VSEA, KSWS,GERN, ATRC Jun 20 2011 
Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
Geron: Buyer Beware Oct 13 2010 
Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 
Geron Corp. (GERN) EVP and CFO David Greenwood sells 14,746 Shares Jun 03 2010 
Geron Corporation Reports 2009 Second Quarter Financial Results and Events Jul 30 2009 
Geron Corp (GERN): Stock of the Day Mar 10 2009 
Banking 60% on the Day the World Changed: FDA Approves Geron to Test Embryonic Stem Cells on Humans Jan 24 2009 
The Next Boom Emerges Nov 23 2008 

More From Other Websites
Why You Shouldn't Bet Against Geron Corporation (GERN) Stock Sep 08 2014
GERON CORP Financials Aug 19 2014
Intercept Pharma Soars On Positive Liver Drug Data Aug 11 2014
Geron Corp Earnings Call scheduled for 4:30 pm ET today Aug 11 2014
GERON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 11 2014
Geron Corporation Reports Second Quarter 2014 Financial Results Aug 11 2014
GERON CORP Files SEC form 10-Q, Quarterly Report Aug 11 2014
Q2 2014 Geron Earnings Release - After Market Close Aug 11 2014
GERON CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Aug 05 2014
Geron to Assume Sponsorship of Myelofibrosis IST and IND Aug 05 2014
Geron Announces Conference Call to Discuss Second Quarter 2014 Financial Results Jul 30 2014
GERON CORP Files SEC form 8-K, Other Events Jul 21 2014
Geron Corp. (GERN) Jumps: Stock Moves 8.1% Higher Jul 01 2014
Geron Set To Explode As FDA Releases Partial Clinical Hold On Imetelstat Myelofibrosis Trial Jun 30 2014
Geron (GERN) Enters Overbought Territory Jun 25 2014
Geron (GERN) Falls: Stock Goes Down 5.4% Jun 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK